Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
Article Abstract:
The drug alendronate may be as beneficial in preventing bone loss as estrogen replacement therapy. This is important because long-term estrogen replacement therapy has side effects. Researchers compared bone density in 1,174 women who took alendronate or a placebo as well as 435 women who took alendronate, a placebo or an estrogen-progestin combination. Women who took a placebo lost bone density at the spine, hip, forearm and whole body. Women who took alendronate gained bone density at most of those sites, and the gain was similar to that in women taking estrogen-progestin.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
Article Abstract:
Raloxifene may increase bone density and decrease cholesterol in postmenopausal women without stimulating the uterine lining to grow. Estrogen can reduce the risk of osteoporosis and cardiovascular disease after menopause, but has been associated with an increased risk of endometrial cancer. Raloxifene therapy increased bone density and reduced bone mineral loss, lowered cholesterol, and did not cause endometrial thickening in 601 women studied for 24 months. Raloxifene may be an effective alternative to estrogen for some postmenopausal women.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial
Article Abstract:
The drug alendronate appears to be effective in preventing bone loss in postmenopausal women. Researchers randomly assigned 447 postmenopausal women to take various dosages of alendronate or a placebo for two years. X-ray absorptiometry every six months showed that alendronate increased bone density at the lower spine and hip by 1% to 4% and in the total body by up to 1%. Women taking a placebo experienced a decline in bone density of 2% to 4%. Alendronate was safe with few side effects.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: New equations to estimate basal metabolic rate in children aged 10-15 years. Basal metabolic rate of women on the contraceptive pill
- Abstracts: Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS: a preliminary report
- Abstracts: Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
- Abstracts: Validity of self-reported sexual behaviors in adolescent women using biomarker outcomes. Sex under the influence: a diary self-report study of substance use and sexual behavior among adolescent women
- Abstracts: Stopping metastases at their source. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer